Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers

British Journal of Cancer

Volumn 115, Issue 4, 2016, Pages 490-496

  Kim, Jung Ho ^a   Park, Hye Eun ^a   Cho, Nam Yun ^b   Lee, Hye Seung ^c   Kang, Gyeong Hoon ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN PMS2; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; BRAF PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1;

ADULT; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CPG ISLAND; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROSATELLITE INSTABILITY; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; AGE; CANCER STAGING; COLORECTAL TUMOR; DNA METHYLATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROMOTER REGION; RETROSPECTIVE STUDY; SEX DIFFERENCE;

AGE FACTORS; ANTIGENS, CD274; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; MUTL PROTEIN HOMOLOG 1; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84978063254     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.211     Document Type: Article

References (28)

1. Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H (2015) Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 14: 149.
2. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26): 2455-2465.
3. Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S (2015) Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res 3(10): 1158-1164.
4. Chen J, Jiang CC, Jin L, Zhang XD (2016) Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 27(3): 409-416.
5. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX (2014) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5: 5241.
6. Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB (2016) Combining epigenetic and immunotherapy to combat cancer. Cancer Res 76(7): 1683-1689.
7. Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC, Cuka N, Argani P, Emens LA (2016) PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 47(1): 52-63.
8. Dudley JC, Lin MT, Le DT, Eshleman JR (2016) Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22(4): 813-820.
9. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, LeabmanM, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528): 563-567.
10. Homet Moreno B, Ribas A (2015) Anti-programmed cell death protein-1/ ligand-1 therapy in different cancers. Br J Cancer 112(9): 1421-1427.
11. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA (2015) Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. 1 JAMA Oncol 1(9): 1319-1323.
12. Jass JR, Ajioka Y, Allen JP, Chan YF, Cohen RJ, Nixon JM, Radojkovic M, Restall AP, Stables SR, Zwi LJ (1996) Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 28(6): 543-548.
13. Kim JH, Bae JM, Oh HJ, Lee HS, Kang GH (2015a) Pathologic factors associated with prognosis after adjuvant chemotherapy in stage II/III microsatellite-unstable colorectal cancers. J Pathol Transl Med 49(2): 118-128.
14. Kim JH, Bae JM, Song YS, Cho NY, Lee HS, Kang GH (2015b) Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma. Oncotarget 7: 13372-13387.
15. Kim JH, Kim KJ, Bae JM, Rhee YY, Cho NY, Lee HS, Kang GH (2015c) Comparative validation of assessment criteria for Crohn-like lymphoid reaction in colorectal carcinoma. J Clin Pathol 68(1): 22-28.
16. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz Jr. LA (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26): 2509-2520.
17. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5(1): 43-51.
18. Lote H, Cafferkey C, Chau I (2015) PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treat Rev 41(10): 893-903.
19. Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L, Li C (2014) Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 110(6): 1595-1605.
20. Mukherji D, Jabbour MN, Saroufim M, Temraz S, Nasr R, Charafeddine M, Assi R, Shamseddine A, Tawil AN (2016) Programmed death-ligand 1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: a reliable treatment selection biomarker? Clin Genitourin Cancer 14(2): 183-187.
21. Prall F, Huhns M (2015) PD-L1 expression in tumour buds of colorectal carcinoma. Histopathology 69: 158-160.
22. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20(19): 5064-5074.
23. Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75(11): 2139-2145.
24. Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4): 450-461.
25. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26): 2443-2454.
26. Wang Y, Wang H, Zhao Q, Xia Y, Hu X, Guo J (2015) PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol 32(8): 212.
27. Xiao Y, Freeman GJ (2015) The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 5(1): 16-18.
28. Zhu H, Qin H, Huang Z, Li S, Zhu X, He J, Yang J, Yu X, Yi X (2015) Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. Int J Clin Exp Pathol 8(8): 9351-9359.